Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Edelberg

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Circulation|February 6, 2002
Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heartJay M Edelberg, Seung H Lee, Manmeen Kaur, et al.
Physiological Genomics|December 15, 2005
BDNF-mediated enhancement of inflammation and injury in the aging heartDongqing Cai, Jacquelyne M Holm, Inga J Duignan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 8, 2006
Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularizationVictoria L T Ballard, Arti Sharma, Inga Duignan, et al.
Journal of Medical Economics|September 8, 2021
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United StatesSneha S Jain, Sophia S Li, Jipan Xie, et al.
Circulation Research|February 14, 2004
Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytesMunira Xaymardan, Lilong Tang, Leze Zagreda, et al.
European Journal of Heart Failure|November 20, 2022
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathyMatthew T Wheeler, Daniel Jacoby, Perry M Elliott, et al.
Journal of the American College of Cardiology|March 11, 2022
Assessment of Disease Status and Treatment Response With Artificial Intelligence-Enhanced Electrocardiography in Obstructive Hypertrophic CardiomyopathyGeoffrey H Tison, Konstantinos C Siontis, Sean Abreau, et al.
Cytometry. Part B, Clinical Cytometry|June 15, 2010
Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic populationAnne M Curtis, Lifeng Zhang, Elizabeth Medenilla, et al.
American Heart Journal|May 26, 2021
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapyMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
JAMA Cardiology|January 18, 2023
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized TrialMatthew T Wheeler, Iacopo Olivotto, Perry M Elliott, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Circulation|February 6, 2002
Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heartJay M Edelberg, Seung H Lee, Manmeen Kaur, et al.
Physiological Genomics|December 15, 2005
BDNF-mediated enhancement of inflammation and injury in the aging heartDongqing Cai, Jacquelyne M Holm, Inga J Duignan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 8, 2006
Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularizationVictoria L T Ballard, Arti Sharma, Inga Duignan, et al.
Journal of Medical Economics|September 8, 2021
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United StatesSneha S Jain, Sophia S Li, Jipan Xie, et al.
Circulation Research|February 14, 2004
Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytesMunira Xaymardan, Lilong Tang, Leze Zagreda, et al.
European Journal of Heart Failure|November 20, 2022
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathyMatthew T Wheeler, Daniel Jacoby, Perry M Elliott, et al.
Journal of the American College of Cardiology|March 11, 2022
Assessment of Disease Status and Treatment Response With Artificial Intelligence-Enhanced Electrocardiography in Obstructive Hypertrophic CardiomyopathyGeoffrey H Tison, Konstantinos C Siontis, Sean Abreau, et al.
Cytometry. Part B, Clinical Cytometry|June 15, 2010
Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic populationAnne M Curtis, Lifeng Zhang, Elizabeth Medenilla, et al.
American Heart Journal|May 26, 2021
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapyMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
JAMA Cardiology|January 18, 2023
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized TrialMatthew T Wheeler, Iacopo Olivotto, Perry M Elliott, et al.
Pageof 6